Phase II trial shows neurocognitive function decline but stable quality of life in first year after temozolomide-based chemoradiotherapy
A secondary analysis of the phase II clinical trial NRG-RTOG 0424, which initially reported a 73.1%…
Browsing: Society for Neuro-Oncology ASM